>>/64463/
Pfizer & Moderna Fail To Respond To British Medical Journal About COVID Vaccine Safety Concerns

June 19, 2021

An article published in the British Medical Journal by Dr. Peter Doshi titled “Covid-19 Vaccines: In The Rush for Regulatory Approval, Do We Need More Data?” raises concerns regarding COVID-19 vaccine rollout, and one of them is the bio-distribution of the vaccine.  

This refers to the examination and study of where the vaccine and its ingredients go once injected into the body. 

Having sped up the approval process of these vaccines, it has been claimed that no compromises in the process of examining their safety were made. But the fact that no study for tracking the distribution of the vaccine within the human body was conducted for any of the authorized vaccines, we cannot say this is true.

Dr. Doshi points out that such bio-distribution studies are a standard practice of drug safety testing but “are usually not required for vaccines.” This in itself is concerning. 

Research regarding the bio-distribution of aluminum containing vaccines, for example, have raised concerns about injected aluminum crossing the blood brain barrier and being distributed throughout the body where it can be detected years after injection. This is important, because vaccines are a different method of delivery than say, ingested aluminum, which the body does a great job of getting rid of through digestion.

Bio-distribution studies weren’t performed for COVID vaccines because data from past studies performed with related, and “mostly unapproved compounds that use the same platform technology” were used to bypass them.

Dr. Doshi points out that,

    --“Pfizer and Moderna did not respond to The BMJ’s questions regarding why no biodistribution studies were conducted on their novel mRNA products, and none of the companies, nor the FDA, would say whether new biodistribution studies will be required prior to licensure.”--

In his article, Dr. Doshi also references a report that Pfizer provided to the Japanese government. In the report there is a table containing lipid nanoparticle bio-distribution data.

    This table shows where their surrogate “vaccine” (i.e. represented in the laboratory test by little bubbles of surrogate fat containing an analytical detection marker) ended up in the body of immunized rats, used in the laboratory as surrogates for humans…I would like to highlight some observations. First…a lot of the surrogate vaccine dose remained at the injection site, as one would expect. 

--Remarkably, however, most of the vaccine dose had gone elsewhere….50-75% of the vaccine dose failed to remain at the site of injection--.

The big question is, where did it go? 

Looking at the other tissues shows some of the paces it went and accumulated…The surrogate vaccine was circulating in the blood. There is also evidence that a substantial amount of the vaccine went to places like the spleen, liver, ovaries, adrenal glands, and bone marrow. The vaccine went to other places as well, such as testes, lungs, intestines, kidneys, thyroid glands, pituitary gland, uterus, etc. The surrogate vaccine tested in a laboratory setting was widely distributed throughout the laboratory animal’s bodies. – Dr. Byram W. Bridle, Viral Immunologist, University of Guelph.

page 1

https://www.lewrockwell.com/2021/06/no_author/pfizer-moderna-fail-to-respond-to-british-medical-journal-about-covid-vaccine-safety-concerns/